The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | The Phase III BELLWAVE-011 study: nemtabrutinib versus investigator’s choice in untreated CLL/SLL
In this video, Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, introduces the Phase III BELLWAVE-011 study (NCT06136559). This large-scale clinical trial will investigate the efficacy and safety of the non-covalent BTK inhibitor (BTKi) nemtabrutinib versus the investigator’s choice of ibrutinib or acalabrutinib in participants with untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This trial is a Phase III clinical trial, very large cohort of patients with many continents involved and we compared the use of non-covalent BTKI, the nemtabrutinib, to the use of covalent BTKi based on the physician’s choice whether it’s acalabrutinib or ibrutinib itself. And that’s quite original because it’s going to be tested at first line...
This trial is a Phase III clinical trial, very large cohort of patients with many continents involved and we compared the use of non-covalent BTKI, the nemtabrutinib, to the use of covalent BTKi based on the physician’s choice whether it’s acalabrutinib or ibrutinib itself. And that’s quite original because it’s going to be tested at first line. So we are going to see whether a non-covalent BTKI will have better toxicity or will have better efficacy in this context. We are now recruiting. I don’t have yet data to present.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory/grant: AbbVie, Johnson&Johnson, Roche, Lilly, AstraZeneca, Takeda.
